Articles tagged with Amyloids
Researchers have found that a protein called transthyretin (TTR) can break toxic amyloid beta clumps associated with Alzheimer's disease. The study suggests that modified TTR peptides may prevent or slow progression of the disease in mouse models, offering new hope for patients.
Researchers found that YKL-40 is regulated by clock genes and involved in clearing away Alzheimer's proteins in the brain. People with lower levels of YKL-40 fare better in terms of cognitive decline, suggesting it may be a potential therapeutic target.
Researchers at Karolinska Institutet identified two alternative pathways for amyloid pathology in Alzheimer's disease, revealing genetic explanations for method discrepancies. The study provides unique biological information for earlier and more individualized diagnosis and treatment.
Researchers discovered that seeds of garden peas contain amyloid-like aggregates of storage proteins, which could lead to less allergenic legume varieties. The formation of these amyloids may also reduce the nutritional value of plant seeds.
A new study found that air pollution in neighborhoods is associated with an increased likelihood of amyloid plaques, a hallmark of Alzheimer's disease. The study suggests that exposure to microscopic airborne particles may be implicated in tens of thousands of cases of the disease.
Researchers found tau accumulation years before dementia symptoms appear in people with Down's syndrome, suggesting an early change. The study suggests potential for early prophylactic measures against tau accumulation to prevent Alzheimer pathology in childhood.
A genetic mutation in the Gga3 gene may be more common among African Americans with late-onset Alzheimer's disease, leading to a 'traffic jam' of enzymes in axons. This discovery provides a possible strategy for early diagnosis and targeted treatments, as well as potential biomarkers for detection.
A University of Missouri researcher has developed procedures to define the preclinical stages of Alzheimer's disease, which can help drug developers identify potential beneficiaries of a future treatment. The study found that 42% of individuals with Alzheimer's-related brain pathology showed no signs of cognitive decline.
Researchers from Heidelberg University have identified the mechanism by which molecular chaperones dissolve amyloid fibrils formed in the brain, a key factor in Parkinson's disease. The study reveals that the chaperone complexes on the surface of the fibrils create strong enough pulling forces to disrupt the aggregates.
A team of researchers has identified a mechanism to target amyloid-beta, a disordered protein involved in Alzheimer's disease. By designing drugs that bind to the protein in its disordered state, they hope to reduce toxic cluster formation and develop new treatments.
Researchers at the University of California - Santa Cruz identify a specific segment of amyloid beta recognized by the cellular prion protein, which mediates its uptake into neurons and toxicity. This finding suggests targeting this process may be a promising approach for Alzheimer's drug development.
Researchers at Massachusetts General Hospital have developed a molecular imaging probe to reveal γ-secretase related to Alzheimer's disease. The study aims to better understand the etiology of AD and facilitate drug discovery.
Researchers at the University of Leeds have visualised the structure of amylin fibrils, a key player in type 2 diabetes, and discovered an intricate architecture that makes some sequences more prone to aggregation. This finding suggests a potential explanation for the rapid onset of disease in individuals with early-onset type 2 diabetes.
Researchers at Korea Brain Research Institute used GANs to analyze bulk RNA-seq data, finding that increased Amyloid-beta in the brain alters cholesterol biosynthesis. This study provides a new approach for projecting biological changes and aiding healthcare industry.
Researchers at Tokyo University of Science used infrared laser irradiation to destroy amyloid fibrils, which are typical of neurodegenerative diseases like Alzheimer's. The study combines experimental and simulation results, showing that the process begins at the core of the fibril, where resonance breaks intermolecular hydrogen bonds.
Studies of alpha-synuclein protein aggregates found variations in elongation rates and fibril structures, depending on cross-seeding and pH levels. High-speed atomic force microscopy enabled visualization of growth over time, shedding light on amyloid-related diseases.
Researchers have identified a blood test target, phosphorylated tau 217, that correlates with the presence of amyloid plaques in the brain. This protein can be detected in the blood of people who have yet to show signs of forgetfulness or confusion, making it a promising tool for early Alzheimer's diagnosis.
A blood test for Alzheimer's disease has shown high accuracy in detecting the disease, with levels of p-tau217 increasing seven-fold in individuals with Alzheimer's. The test detected tau brain changes 20 years before cognitive impairment in those with a genetic predisposition.
Researchers discovered that low-concentration salt crystals can precipitate at nanoscales due to local density fluctuation, accelerating amyloid-β peptide aggregation. This process could provide a permanent solution for Alzheimer's disease treatment.
Researchers at Washington University School of Medicine have developed a technique to detect minute amounts of p-tau-217, a protein fragment linked to Alzheimer's disease in the blood. The levels of this protein are elevated during the early stages of the disease and can accurately predict the presence of amyloid plaques in PET scans.
Researchers discovered that garden peas can form highly stable amyloid protein aggregates, which may aid in seed longevity. Vicilin and its domains were found to co-localize with amyloid-specific dye in pea seeds.
A research team mapped molecular changes in cells near amyloid plaques, finding two co-expression networks that respond to amyloid beta deposition. These networks, expressed by astroglia, microglia, and oligodendrocytes, show both protective and damaging effects on the brain, highlighting the complexity of Alzheimer's disease.
The AHEAD 3-45 study is a Phase III clinical trial aiming to prevent worsening memory and thinking among individuals at risk for future decline. Researchers hope to find that BAN2401 can help prevent Alzheimer's disease.
Research at SNMMI 2020 Annual Meeting found super-agers have lower tau and amyloid pathology associated with neurodegeneration. This enables them to maintain their cognitive skills even at advanced ages. The study suggests a potential pathway for successful aging and developing novel treatments to tackle age-related diseases.
A new study suggests that misfolded protein build-up in the gut may contribute to Alzheimer's-like symptoms in mice, potentially leading to a new treatment approach targeting the gut. The researchers found that beta amyloid proteins injected into the gut traveled to the nervous system and brain, causing cognitive impairments.
Researchers found that neurons with high remodeling activity are more vulnerable to Alzheimer's disease and die when their remodeling goes awry. The study, which linked amyloid-beta and tau proteins at the genetic and molecular levels, provides insights into the disease's progression.
Researchers provide new understanding of co-aggregation process between proinflammatory S100A9 protein and Aβ42 peptide in Alzheimer's disease. The study reveals that S100A9 amyloids coat the surface of Aβ42 amyloids, reducing secondary nucleation sites and enhancing cellular toxicity.
A newly discovered gene RBFOX1 may drive the first appearance of amyloid plaques in the brain, contributing to Alzheimer's disease. The study found that variants of RBFOX1 increase protein fragments making up amyloid plaques and disrupt critical connections between neurons.
Researchers found amyloid β protein fibrillation slowed down in microgravity, resulting in distinct morphologies. The study provides fundamental insights into pathological amyloid formation, highlighting the ISS as an ideal experimental environment.
Researchers have created new antiviral molecules by designing synthetic amyloid peptides that can inactivate viral proteins, thereby interfering with viral replication. These 'Pept-ins' specifically target the influenza A and Zika virus proteins.
Researchers develop lab-engineered model of human blood-brain barrier, discovering how APOE4 variant causes amyloid protein plaques to disrupt brain's vasculature. They identify specific vascular cell type and molecular pathway that promotes cerebral amyloid angiopathy pathology.
Researchers developed a single-molecule orientation imaging approach to study amyloid proteins, revealing nanoscale differences in their structures. The method provides insights into the fundamental biological mechanisms of disease, potentially contributing to the development of effective therapeutics.
Researchers have developed an antibody that can accurately detect and quantify toxic amyloid-beta oligomers, a hallmark of Alzheimer's disease. This discovery could lead to improved diagnostic methods and ultimately help monitor the progression of the disease.
Researchers found that acetylation at lysine 16 leads to disordered aggregates with high toxicity, highlighting the importance of protein shape in amyloid beta toxicity. The study aims to better understand the complexity of misfolded proteins and their role in neurodegenerative diseases like Alzheimer's.
Researchers at University of Malaga's BacBio laboratory have identified a new role for an amyloid protein, improving biological control methods in sustainable agriculture. The study reveals the dual functionality of the protein, which helps bacterial cells attach to plant surfaces, combat pathogens and improve fitness.
A study using mouse models of Alzheimer's disease found that high calcium levels in mitochondria are associated with plaque deposition and neuronal death. Researchers propose targeting calcium entry to the mitochondria as a promising new therapeutic approach.
Researchers developed simple molecular reagents that can simultaneously target and modulate various pathogenic factors in Alzheimer's disease. The reagents displayed redox-dependent reactivities against free radicals, metal-free and metal-bound amyloid-beta, and led to chemical modifications that altered its aggregation.
Researchers developed a compound that significantly reduced amyloid plaques, lessened brain inflammation, and diminished molecular markers of Alzheimer's disease. The findings suggest that drugs targeting different regions of amyloid-beta protein fragments and metal ions could improve outcomes for people with Alzheimer's.
Researchers used CRISPR/Cas9 to search for genes related to Alzheimer's disease and found that low levels of CIB1 lead to high amyloid beta production. The study suggests that regulating CIB1 and gamma secretase could be a new target for Alzhemier's disease therapy.
Researchers used high-speed atomic force microscopy to visualize the formation of Sup35NM amyloid fibrils in real time. They discovered that oligomers and fibrils have distinct structural characteristics, challenging previous assumptions about their relationship.
The A4 study found that higher levels of the amyloid protein in the brain are associated with an early stage of Alzheimer's disease. The study analyzed data from 4,486 participants and showed that amyloid burden is linked to a family history of disease, lower cognitive test scores, and reports of daily cognitive decline.
Researchers have identified a gene, endothelin-converting enzyme 2 (ECE2), that significantly increases the risk of Alzheimer's disease. The study found two mutations in ECE2 impairing its ability to break down amyloid beta protein, leading to increased levels and plaque formation.
A study published in eLife found that amyloid plaque formation directly causes brain tissue loss in animals, leading to progressive memory loss and loss of brain matter. However, lithium has been shown to reduce the life-shortening effects of this loss, suggesting a potential strategy to slow Alzheimer's disease progression.
Researchers suggest that infectious agents may play a role in Alzheimer's disease, challenging the current amyloid hypothesis. Recent studies have linked certain viruses and bacteria to AD pathology, sparking fresh interest in this unorthodox approach.
A study reveals that Alzheimer risk genes are linked to microglia's response to amyloid-beta, a key protein in the disease. The researchers identified 11 new risk genes that are upregulated when facing increased amyloid-beta levels.
Researchers have discovered a new role for amyloids in memory storage. They found that Orb2 protein self-aggregates form biochemically active aggregates at synapses, promoting synaptic translation and memory persistence. This finding challenges the traditional view of amyloids as neurotoxic structures.
Researchers have made a groundbreaking finding by using gold nanoparticles to label and visualize amyloid fibrils in their natural state. This breakthrough has significant implications for understanding the mechanisms of Alzheimer's disease and developing new treatments.
Researchers found that interferon triggers a cascade of inflammatory reactions leading to synapse loss and neuronal dysfunction in Alzheimer's disease. The study also suggests that blocking the IFN-triggered cascade could potentially reduce microglia activation and synapse loss.
Researchers developed a small molecule that can modify the coordination sphere of copper bound to amyloid-β, inhibiting its aggregation and toxicity. The study offers insights into chemically modifying neurotoxicity in Alzheimer's disease.
Researchers found that a protein called FRX1 functions in an amyloid form in healthy brains, contradicting the idea that only diseased brains store amyloids. This discovery has significant implications for the treatment of neurodegenerative diseases.
Scientists at Newcastle University have discovered a link between amyloid-beta levels in the blood and cardiovascular disease. Higher levels of amyloid-beta may indicate a higher risk of developing serious heart complications, such as heart failure and progression to heart disease.
Scientists at Chiba University discovered that human cells have a system to capture and degrade aberrant extracellular proteins. The research found that Clusterin, an extracellular molecular chaperone, selectively binds to amyloid β and forms a complex that is taken up by cells via the heparan sulfate receptor.
New research found that the accumulation of tau and amyloid proteins in the brain significantly alters gene expression, particularly in genes related to inflammation. The study provides new insights into the progression of Alzheimer's disease and highlights potential pathways for treatment.
A newly identified compound, C1, is a covalent gamma-secretase inhibitor that blocks the production of amyloids by inhibiting the enzyme's activity on the amyloid precursor protein. This approach avoids traditional enzyme inhibitors' severe side effects and shows promise for treating Alzheimer's disease.
Scientists develop a mathematical model that describes the chemical reactions responsible for amyloid fibril formation, revealing catalytic sites at interfaces and implications for laboratory data interpretation. The model has a simpler mathematical form than previous models, making it more accessible for future studies.
Researchers have identified a new protein called 'aggregatin' that accumulates in brain plaques and may be linked to Alzheimer's disease progression. Suppressing this protein could lead to future treatments aimed at slowing the disease's advance.
Scientists discovered a key mechanism underlying Alzheimer's pathology, revealing how amyloid-beta oligomers hijack norepinephrine signaling to activate GSK3-beta and hyper-phosphorylate tau protein. This rewiring of the alpha-2A adrenergic receptor may explain the failure of previous clinical trials targeting amyloid protein buildup.
A protein associated with ovarian cancer may contribute to the progression of Alzheimer's disease by impairing mitochondria function and causing neuronal damage. Researchers have identified OCIAD1 as a potential therapeutic target for the disease.
A Brazilian research team identified the presence of mutant p53 protein clusters in chemotherapy-resistant glioblastoma cells, which can lead to drug resistance. The study found that these clusters are organized in a way that makes them resistant to temozolomide, a common treatment for the disease.
A new study finds that tau protein is a more reliable predictor of brain atrophy in Alzheimer's patients than amyloid plaques. Tau PET imaging technology has the potential to accelerate clinical trials and improve individualized patient care.